Parkinson’s disease is a debilitating disorder characterised by movement disorders, including tremor, cognitive dysfunction and non-motor impairments. It is the second most common age-related neurodegenerative disease with ~10 million sufferers worldwide, but the causes of tremor are poorly understood and treatment is wholly inadequate.
Royal College of Surgeons Ireland (RCSI)
α-Synuclein (α-Syn) pathology is inextricably linked to the pathogenesis of Parkinson’s disease (PD), yet we have very limited understanding why specific neuronal populations are vulnerable to α-Syn-related PD pathology while others are much more resistant.
Project Aim(s):
(i) To Identify tiRNA/sncRNA fingerprints in AD, ALS, FTD and PD human disease i-neurons.
(ii) To determine if tiRNAs affect the survival of i-neurons from controls and ALS, PD and FTD models.
Project Aim(s): PD-MitoQUANT is an Innovative Medicines Initiative (IMI)Innovative Medicines Initiative (IMI) (www.imi.europa.eu) project that brings together academic experts, small and medium enterprises (SMEs), pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA)European Federation of Pharmaceutical Industries and Associations (EFPIA) (www.efpia.eu) and patient advocacy organisation Parkinson’s UKParkinson’s UK (www.p
Project Aim(s): The aim of RNA-NEURO is to reveal the role of small non-coding RNAs in Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia, with a view to creating novel therapeutic strategies to treat these disorders.
Project Aim(s): To perform a systematic analysis of tiRNA – protein complexes in ALS and Epilepsy models as well as samples from patients.